Genetic engineering concept. Medical science. Scientific Laboratory.
image-

Applied DNA and EvviVax Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy

Posted on

– First Published Study Demonstrates LinearDNA Pan-Cancer and Colon Cancer Neoantigen – – Targeted Vaccines Elicit a Therapeutic Immune Response in Animal Cancer Models – – LinearDNA Vaccines Elicits Strong Antigen-specific Immune Responses and Significantly Reduces Tumor Growth – – Manuscript Summarizing Findings Posted to Preprint Server and Submitted for Peer-Reviewed Publication – STONY BROOK, […]

Read More email

image-

Research Publication Demonstrates Utility of Applied DNA’s LinearDNA™ in Non-Viral CAR T Manufacturing Systems

Posted on

Preclinical Study Details Application of LinearDNA Suitable for the Cost-Effective Production of CAR T Cells Results Demonstrate that CAR19 T-cells Manufactured with LinearDNA Have Similar Efficacy to CAR19 T-cells Manufactured with Plasmid DNA STONY BROOK, N.Y. – November 9, 2021 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction […]

Read More email

image-

Research Publication Demonstrates Utility of Applied DNA’s LinearDNA™ in Non-Viral CAR T Manufacturing

Posted on

STONY BROOK, N.Y. – November 9, 2021 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced the publication of a study in Molecular Therapy: Methods and Clinical Development on a methodology for the manufacture of novel types of […]

Read More email

image-

Applied DNA Announces Linear DNA Orders from New Contract Research Customers for Use in RNA Vaccine and Adeno-Associated Virus Applications

Posted on

STONY BROOK, N.Y. – November 2, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that it received orders for its linear DNA to be evaluated in an RNA vaccine and Adeno-Associated Virus (AAV) production from two new contract research customers, […]

Read More email

image-

Applied DNA Ships LinearDNA™ to Another Development Customer

Posted on

STONY BROOK, N.Y., March 26, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, announced today that it has shipped two CAR T amplicons proprietary to […]

Read More email

image-

APDN Secures Top-20 Pharmaceutical Manufacturer as Drug Development Customer

Posted on

STONY BROOK N.Y., March 20, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions, nucleic acid-based biotherapeutic development, and liquid biopsies for cancer diagnostics, announced today that it has signed a Research Agreement (the “Agreement”) with a global […]

Read More email

image-

Medicare Coverage of CAR T-Cell Therapy Holds Positive Implications for LineaRx

Posted on

STONY BROOK, NY. August 12, 2019 – LineaRx, Inc. (“LineaRx”), a majority-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) announced that, in a decision rendered on August 7, 2019, the Centers for Medicare and Medicaid Services (CMS) approved chimeric antigen receptor (CAR) T-cell therapies that fit the CMS criteria […]

Read More email

image-

LineaRx Achieves Anti-CD19 Expression in Human CAR T Cells via Plasmid-Free Platform

Posted on

STONY BROOK N.Y., April 8, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) announced today that LineaRx, (the “Company”), its subsidiary focused on next-generation biotherapeutics, has achieved anti-CD-19 CAR (Chimeric Antigen Receptor) expression in human T Cells via its proprietary, non-viral, plasmid-free (NVPF) manufacturing platform. To the Company’s knowledge, this seminal event represents the first […]

Read More email

image-

LineaRx to Announce DNA Vaccine Preclinical Data and Efficacy of In-Licensed CAR T Therapy

Posted on

[vc_column_text el_class=”graphic”]STONY BROOK N.Y., December 4, 2018 – LineaRx, Inc., the biotherapeutics company based on the use of large-scale production of gene-sized DNA by Polymerase Chain Reaction (“PCR”) and dedicated to revolutionizing biotherapeutics for the masses in affordability, availability, time-to-market, and reducing the risk associated with virally mediated therapy, and a wholly-owned subsidiary of Applied […]

Read More email

image-

At LineaRX, Putting The Horsepower Behind The CAR T

Posted on

[vc_single_image image=”15087″ img_size=”large”] Unique position: With its next-level ability to produce DNA constructs, Stony Brook startup LineaRX is looking to speed up production of critical, anti-cancer chimeric antigen receptor modified T cell (or CAR T) therapies. By GREGORY ZELLER //OCTOBER 16, 2018 Marking a big step in the war against cancer, a Stony Brook-based startup […]

Read More email

image-

Non-Viral, Plasmid-Free CAR T-Manufacturing Platform Begins Preclinicals

Posted on

[vc_single_image image=”14679″ img_size=”full”] Streamlined manufacturing processes could yield reduced cost and lead times, lessening patient morbidity and mortality through shorter “vein-to-vein” times. [Applied DNA Sciences] By MaryAnn Labant A rapidly emerging immunotherapy approach, adoptive cell transfer (ACT), collects and uses a patient’s own immune cells to treat their cancer. One methodology, Chimeric Antigen Receptor T-Cell (CAR T-cell) […]

Read More email

image-

LineaRx Licenses CAR T Drug Candidate, Initiates Pre-Clinical Development of Non-viral, Plasmid-free CAR T Manufacturing Platform

Posted on

STONY BROOK, N.Y., October, 16, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), the leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has initiated pre-clinical development of a non-viral, plasmid-free (NVPF) chimeric antigen receptor (CAR) modified T cell (CAR […]

Read More email